BTIG analyst Mark Massaro reiterated a Buy rating on Guardant Health (GH – Research Report) yesterday and set a price target of $60.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback